| |
|
BCT History |
Bio-Cancer Treatment International Limited (BCT) is a Hong
Kong-based biotechnology company founded by Dr. Paul N.M. Cheng, a
Memorial Kettering Cancer Center Trained medical
oncologist/hematologist, and his partner, Dr. Jun Sing Lee, a Johns
Hopkins PhD in Engineering, in 2001.
A local team of young scientists headed by Dr. Cheng and two
outstanding bio-tech experts at the Hong Kong Polytechnic
University, Dr. Thomas Lo, a MIT-trained fermentation expert and Dr.
Thomas Leung, an Oxford University graduate specializing ... |
|
 |
|
|
|
|
|
Company News |
|
|
|
A Phase I study of the safety and preliminary efficacy of PEG-BCT-100 in pa...  |
23/4/2012 |
|
PEG-BCT-100(rhArgI-peg5000) IND application approved by FDA...... |
15/3/2012 |
|
|
|
Product |
|
BCT-100
BCT-100 is a recombinant human arginase in
phosphate saline buffer for intravenous injection use
only. It is presently a drug under clinical studies and
if approved, it will be indicated for the treatment of
hepatocellular carcinoma, refractory myeloid leukemia, T
cell Acute Lymphoblastic leukemia, breast, prostate and
renal cancers. Please contact us for details in
formulation. |
|
Methoxy poly(ethylene glycol) succinimidyl propionate
(mPEG-SPA)
mPEG-SPA MW 5,000 Dalton (AR grade)
mPEG-SPA MW 5,000 Dalton (USP-compliant grade)
mPEG-COOH MW 5,000 Dalton (AR grade)
mPEG-COOH MW 5,000 Dalton (USP-compliant grade) |
|
|
